Skip to Main Content

WASHINGTON — An effort to use congressional legislation to incentivize the development of new antibiotics fell short Wednesday, despite lobbying pressure from pharmaceutical companies and medical societies.

Antibiotics are rarely moneymakers for drug makers, and yet there’s wide agreement that there’s a need for more given that some bacteria are increasingly resistant to the therapies currently on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • If our senator’s aren’t going to do anything to improve life for Americans. Maybe they should at least legalize physician assisted suicide. So we can at least die with some dignity. Instead of the slow painful way they are doing to pain patients.

Comments are closed.